Close

Novartis AG recalls 4 over-the-counter drugs

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Novartis AG said Sunday it is voluntarily recalling some over-the-counter products in the U.S., including its Excedrin headache pills and NoDoz medication, because they may contain broken or stray tablets from other products.

The recall also affects its Bufferin and Gas-X Prevention brands.Novartis has temporarily suspended operations at the Lincoln, Neb., plant where the products were made, the company said in a statement.The move comes after consumer complaints “of chipped and broken pills and inconsistent bottle packaging line clearance practices possibly resulting in mixed tablets,” the company said. The over-the-counter medications were distributed throughout the U.S.

Julie Masow, a spokeswoman for the Basel, Switzerland-based company, said she didn’t immediately have a number for the amount of tablets and gel caps involved in the recall. She said there hadn’t been any reports of overdoses or allergic reactions from the stray material or broken and chipped medication. The Lincoln facility’s products account for less than 2 percent of Novartis Group sales, Novartis said. The drugmaker had sales of $50.6 billion in 2010.

The company said it was recalling all lots of bottles containing Excedrin and NoDoz with expiration dates of Dec. 20, 2014, or earlier, as well as Bufferin and Gas-X Prevention with throw-out dates of Dec. 20, 2013, or earlier.

 

Latest stories

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back